KLK3 and prostate cancer: Chen et al. utilised SERS of blood serum as a screening tool to differentiate between prostate cancer and benign prostatic hyperplasia (BPH) in males with prostate-specific antigen levels in the 4–10 ng/mL range, which represents a major diagnostic challenge [73].